David R. Anderson

David R. Anderson

Auto-generated profile, based on publicly available information

David R. Anderson

Department of Medicine, Dalhousie University, Halifax, NS, Canada

Research Focus & Metrics

Academic Career Length

22Years (2005-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
22 February 2018 in New England Journal of Medicine
Verified
Journal Article
Closed access
PDF file
DADavid R. Anderson
David R. Anderson
MDMichael Dunbar
Michael Dunbar
JMJohn Murnaghan
John Murnaghan
SKSusan R. Kahn
Susan R. Kahn
PGPeter Gross
Peter Gross
PVPascal-André Vendittoli
Pascal-André Vendittoli
Clinical trials and meta-analyses have suggested that aspirin may be effective for the prevention of venous thromboembolism (proximal deep-vein thrombosis or pulmonary embolism) after total hip or total knee arthroplasty, but comparisons with direct oral anticoagulants are lacking for prophylaxis beyond hospital discharge. We performed a multicenter, double-blind, randomized, controlled trial involving patients who were undergoing total hip or knee arthroplasty. All the patients received once-daily oral rivaroxaban (10 mg) until postoperative day 5 and then were randomly assigned to continue rivaroxaban or switch to aspirin (81 mg daily) for an additional 9 days after total knee arthroplasty or for 30 days after total hip arthroplasty. Patients were followed for 90 days for symptomatic venous thromboembolism (the primary effectiveness outcome) and bleeding complications, including major or clinically relevant nonmajor bleeding (the primary safety outcome). A total of 3424 patients (1804 undergoing total hip arthroplasty and 1620 undergoing total knee arthroplasty) were enrolled in the trial. Venous thromboembolism occurred in 11 of 1707 patients (0.64%) in the aspirin group and in 12 of 1717 patients (0.70%) in the rivaroxaban group (difference, 0.06 percentage points; 95% confidence interval [CI], −0.55 to 0.66; P<0.001 for noninferiority and P=0.84 for superiority). Major bleeding complications occurred in 8 patients (0.47%) in the aspirin group and in 5 (0.29%) in the rivaroxaban group (difference, 0.18 percentage points; 95% CI, −0.65 to 0.29; P=0.42). Clinically important bleeding occurred in 22 patients (1.29%) in the aspirin group and in 17 (0.99%) in the rivaroxaban group (difference, 0.30 percentage points; 95% CI, −1.07 to 0.47; P=0.43). Among patients who received 5 days of rivaroxaban prophylaxis after total hip or total knee arthroplasty, extended prophylaxis with aspirin was not significantly different from rivaroxaban in the prevention of symptomatic venous thromboembolism. (Funded by the Canadian Institutes of Health Research; ClinicalTrials.gov number, NCT01720108.)

1 May 2007 in Journal of Medicinal Chemistry
Verified
Journal Article
Closed access
DADavid R. Anderson
David R. Anderson
MMMarvin J. Meyers
Marvin J. Meyers
WVWilliam F. Vernier
William F. Vernier
MMMatthew W. Mahoney
Matthew W. Mahoney
RKRavi G. Kurumbail
Ravi G. Kurumbail
RMRobert J. Mourey
Robert J. Mourey

1 December 2005 in Journal of Critical Care
Verified
Journal Article
Closed access
DCDeborah Cook
Deborah Cook
JDJames Douketis
James Douketis
MCMark A. Crowther
Mark A. Crowther
DADavid R. Anderson
David R. Anderson

24 April 2013 in Catheterization and Cardiovascular Interventions
Verified
Journal Article
Open access
PDF file
UJUsman Javed
Usman Javed
CBChristopher R. Balwanz
Christopher R. Balwanz
EAEhrin J. Armstrong
Ehrin J. Armstrong
KYKhung‐Keong Yeo
Khung‐Keong Yeo
GSGagan D. Singh
Gagan D. Singh
JLJohn R. Laird
John R. Laird
Objectives: We sought to evaluate the procedural characteristics and clinical outcomes of endovascular repair for iliac artery (IA) in‐stent restenosis (ISR).Background: An increasing percentage of patients with complex IA occlusive disease are treated with an endovascular approach, but the outcomes of IA‐ISR have not been well described.Methods: We analyzed all endovascular procedures for treatment of IA‐ISR performed at our institution between July 2006–December 2010. The primary outcome was primary patency, defined as <50% stenosis as assessed by clinical examination and duplex ultrasonography (DUS).Results: Forty‐one lesions in 24 patients who underwent repeated endovascular intervention for treatment of IA‐ISR. Most lesions were unilateral and involved the common IA (66%). The mean length of ISR was 30.1 ± 14.1 mm with type I (focal) and II (diffuse) ISR occurring with the greatest frequency (34% and 39%, respectively). All patients underwent balloon angioplasty; adjunctive stenting zwas performed in 27 (66%) of the lesions. Type II ISR lesions more frequently required stenting (13/16 lesions, P = 0.02 compared with other patterns of ISR). Procedural success was 100% with a mean gain of 0.13 in the ankle‐brachial index (P = 0.001). The 6‐ and 12‐month primary patency rates were 96% and 82%, respectively. The 12‐month primary‐assisted patency rate was 90% with clinically driven target lesion revascularization (TLR) in three patients.Conclusions: Endovascular treatment of IA‐ISR using an approach of balloon angioplasty followed by selective stenting is associated with high‐patency rates and low rates of TLR at 1 year.

1 February 2017 in The Annals of Thoracic Surgery
Verified
Journal Article
Closed access
PDF file
MYMartin T. Yates
Martin T. Yates
DADavid R. Anderson
David R. Anderson

12 November 2026 in New England Journal of Medicine
Verified
Journal Article
Closed access
SSSudeep Shivakumar
Sudeep Shivakumar
DMDavide Matino
Davide Matino
DZDavid Zukor
David Zukor
SKSusan R Kahn
Susan R Kahn
GVGeorge Vincent
George Vincent
EIEPCAT III Trial Investigators
EPCAT III Trial Investigators
Aspirin after an initial short course of rivaroxaban has been shown to be safe and effective for the prevention of venous thromboembolism after total hip or total knee arthroplasty, but uncertainty remains about the use of aspirin alone. In this multicenter, double-blind, randomized, controlled trial, we assigned patients to receive once-daily thromboprophylaxis with either 81 mg of aspirin or 10 mg of oral rivaroxaban for the first 5 days after total hip or total knee arthroplasty. All the patients then received further thromboprophylaxis with 81 mg of aspirin daily for 9 additional days after knee arthroplasty and for 30 additional days after hip arthroplasty. Patients were followed for 90 days for symptomatic venous thromboembolism, which consisted of either proximal deep-vein thrombosis or pulmonary embolism (primary effectiveness outcome), and for bleeding complications (primary safety outcome). The noninferiority margin for aspirin alone as compared with rivaroxaban-aspirin was 0.7 percentage points. A total of 5429 patients underwent randomization. Venous thromboembolism developed in 13 of 2718 patients (0.48%) in the aspirin-alone group and in 12 of 2647 patients (0.45%) in the rivaroxaban-aspirin group (risk difference, 0.02 percentage points; 95% confidence interval [CI], -0.34 to 0.39; P<0.001 for noninferiority). Major bleeding or clinically relevant nonmajor bleeding events occurred in 45 of 2718 patients (1.66%) in the aspirin-alone group and in 54 of 2647 patients (2.04%) in the rivaroxaban-aspirin group (risk difference, -0.38%; 95% CI, -1.11 to 0.34). After total hip and total knee arthroplasty, the use of aspirin alone was not inferior to a strategy of using rivaroxaban followed by aspirin for the prevention of symptomatic venous thromboembolism, with no clinically relevant difference in bleeding events. (Funded by the Canadian Institutes of Health Research; EPCAT III ClinicalTrials.gov number, NCT04075240.).